Effect of aminoglycoside and β-lactam combination therapy versus β-lactam monotherapy on the emergence of antimicrobial resistance:: A meta-analysis of randomized, controlled trials

被引:151
作者
Bliziotis, IA
Samonis, G
Vardakas, KZ
Chrysanthopoulou, S
Falagas, ME
机构
[1] Henry Dunant Hosp, Alfa Inst Biomed Sci, Athens, Greece
[2] Henry Dunant Hosp, Dept Med, Athens, Greece
[3] Univ Crete, Dept Med, Sch Med, Iraklion, Greece
[4] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA
关键词
D O I
10.1086/430912
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The addition of an aminoglycoside to a Beta-lactam therapy regimen has been suggested to have a beneficial effect in delaying or preventing the development of antimicrobial resistance. We studied the effect of aminoglycoside/beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of resistance. Methods. We performed a meta-analysis of randomized, controlled trials (RCTs) that compared aminoglycoside/beta-lactam combination therapy with beta-lactam monotherapy and that reported data regarding the emergence of resistance (primary outcome) and/or development of superinfection, treatment failure, treatment failure attributable to emergence of resistance, treatment failure attributable to superinfection, all-cause mortality during treatment, and mortality due to infection. Data for this meta-analysis were identified from the PubMed database, Current Contents database, Cochrane central register of controlled trials, and references in relevant articles. Results. A total of 8 RCTs were included in the analysis. beta-Lactam monotherapy was not associated with a greater emergence of resistance than was the aminoglycoside/b-lactam combination (odds ratio [OR], 0.90; 95% confidence interval [CI], 0.56 - 1.47). Actually, beta-lactam monotherapy was associated with fewer superinfections (OR, 0.62; 95% CI, 0.42 - 0.93) and fewer treatment failures (OR, 0.62; 95% CI, 0.38 - 1.01). Rates of treatment failure attributable to emergence of resistance (OR, 3.09; 95% CI, 0.75 - 12.82), treatment failure attributable to superinfection (OR, 0.60; 95% CI, 0.33 - 1.10), all-cause mortality during treatment (OR, 0.70; 95% CI, 0.40 - 1.25), and mortality due to infection (OR, 0.74; 95% CI, 0.46 - 1.21) did not differ significantly between the 2 regimens. Conclusions. Compared with b-lactam monotherapy, the aminoglycoside/beta-lactam combination was not associated with a beneficial effect on the development of antimicrobial resistance among initially antimicrobial-susceptible isolates.
引用
收藏
页码:149 / 158
页数:10
相关论文
共 85 条
  • [31] COMPARISON OF ONCE DAILY CEFTRIAXONE WITH GENTAMICIN PLUS CEFUROXIME FOR TREATMENT OF SERIOUS BACTERIAL-INFECTIONS
    HOEPELMAN, IM
    ROZENBERGARSKA, M
    VERHOEF, J
    [J]. LANCET, 1988, 1 (8598) : 1305 - 1309
  • [32] Meropenem versus cefuroxime plus gentamicin for treatment of serious infections in elderly patients
    Jaspers, CAJJ
    Kieft, H
    Speelberg, B
    Buiting, A
    Kooij, MV
    Ruys, GJHM
    Vincent, HH
    Vermeulen, MCA
    Olink, AG
    Hoepelman, IM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (05) : 1233 - 1238
  • [33] JOHNSON DE, 1986, AM J MED, V80, P53
  • [34] EFFICACY OF CEFAZOLIN, CEFAMANDOLE, AND GENTAMICIN AS PROPHYLACTIC AGENTS IN CARDIAC-SURGERY - RESULTS OF A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND TRIAL IN 1030 PATIENTS
    KAISER, AB
    PETRACEK, MR
    LEA, JW
    KERNODLE, DS
    ROACH, AC
    ALFORD, WC
    BURRUS, GR
    GLASSFORD, DM
    THOMS, CS
    STONEY, WS
    [J]. ANNALS OF SURGERY, 1987, 206 (06) : 791 - 797
  • [35] KARCHMER AW, 1983, REV INFECT DIS, V5, pS543
  • [36] Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp.
    Kaye, KS
    Cosgrove, S
    Harris, A
    Eliopoulos, GM
    Carmeli, Y
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (09) : 2628 - 2630
  • [37] PROSPECTIVE OBSERVATIONAL STUDY OF KLEBSIELLA BACTEREMIA IN 230 PATIENTS - OUTCOME FOR ANTIBIOTIC COMBINATIONS VERSUS MONOTHERAPY
    KORVICK, JA
    BRYAN, CS
    FARBER, B
    BEAM, TR
    SCHENFELD, L
    MUDER, RR
    WEINBAUM, D
    LUMISH, R
    GERDING, DN
    WAGENER, MM
    YU, VL
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (12) : 2639 - 2644
  • [38] COMBINATION ANTIMICROBIAL THERAPY FOR STAPHYLOCOCCUS-AUREUS ENDOCARDITIS IN PATIENTS ADDICTED TO PARENTERAL DRUGS AND IN NON-ADDICTS - A PROSPECTIVE-STUDY
    KORZENIOWSKI, O
    SANDE, MA
    [J]. ANNALS OF INTERNAL MEDICINE, 1982, 97 (04) : 496 - 503
  • [39] KOSMIDIS J, 1986, SCAND J INFECT DIS, P135
  • [40] Kriaras I, 1997, J CARDIOVASC SURG, V38, P605